Cyclophosphamide for multiple sclerosis-Reference-Cited by-同舟云学术

Cyclophosphamide for multiple sclerosis

Published:2007-01-24 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

La Mantia Loredana¹,Milanese Clara¹,Mascoli Nerina¹,D'Amico Roberto²,Weinstock-Guttman Bianca³

Affiliation:

1. Fondazione I.R.C.C.S. - Istituto Neurologico C. Besta; MS Group; Via Celoria, 11 Milano Italy 20133

2. University of Modena and Reggio Emilia; Department of Oncology and Hematology; Via del Pozzo 71 Modena Italy

3. The Jacobs Neurological Institute, State University of New York at Buffalo; Baird MS Center; 100 High Street Buffalo New York USA 14203

Publisher

Wiley

Subject

Pharmacology (medical)

Reference117 articles.

1. Immunosuppression for multiple sclerosis (Letter) [comment on: N Engl J Med 1983; 308: 173-80];Fishbeck;The New England Journal of Medicine,1983

2. Controlled randomized trial of high-dose cyclophosphamide, plasmapheresis and ACTH in progressive multiple sclerosis (Abstract);Hauser;Neurology,1982

3. Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis. Design of a clinical trial;Hauser;Archives of Neurology,1983

4. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH [comment in: N Engl J Med 1983; 309: 239-40; comment in: N Engl J Med 1983; 309: 241; comment in: Lancet 1991; 337:1540-1];Hauser;The New England Journal of Medicine,1983

5. immunosuppression for multiple sclerosis (Letter) [Comment on: N Engl J Med 1983; 308: 173-80];Hauser;The New England Journal of Medicine,1983

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7;Cell Calcium;2024-11

2. Disease modifying treatment guidelines for multiple sclerosis in the United Arab Emirates;Multiple Sclerosis and Related Disorders;2024-08

3. Rationale for off-label treatments use in primary progressive multiple sclerosis: A review of the literature;Revue Neurologique;2022-11

4. Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases;Physiological Reviews;2022-04-01

5. Progress in the Application of Drugs for the Treatment of Multiple Sclerosis;Frontiers in Pharmacology;2021-07-13